Persistent Anemia After Hemopoietic Cell Transplantation

  • Aleksandar Mijovic
Chapter

Abstract

A male patient in first remission of acute myeloid leukemia was offered a hemopoietic cell transplant from an unrelated female donor. He received reduced-intensity conditioning (RIC) with Fludarabine 30 mg/m2 iv × 5 day, Busulphan 3.2 mg/kg iv × 2 days, and Alemtuzumab 20 mg/day iv × 5 days, followed by donor blood stem cell infusion. The cell dose was 3.7 × 106 CD34+ cells per kilogram recipient weight. Cyclosporine A was administered from day +1.

Keywords

Leukemia Anemia Bilirubin Cyclosporine Vancomycin 

References

  1. Bolan CD, Leitman SF, Griffith LM, et al. Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation. Blood. 2001;98:1687–94.PubMedCrossRefGoogle Scholar
  2. Mijovic A, Abdallah A, Pearce L, et al. Effects on erythropoiesis of alemtuzumab-containing reduced intensity and standard conditioning regimes. Br J Haematol. 2008;142:444–52.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London Limited 2012

Authors and Affiliations

  • Aleksandar Mijovic
    • 1
  1. 1.Kings College Hospital HaematologyLondonUK

Personalised recommendations